SUTRO BIOPHARMA INC
For the period ended Dec 31, 2024. Filed Mar 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 13, 2025
STRO$10.61+10.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In- · Comprehensive · Accumulated · Stockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balances at December 31, 2021 | 46,327,131 | $46 | $586,243 | $(314) | $(333,411) | $252,564 |
| Exercise of common stock options | 49,654 | - | 268 | - | - | 268 |
| Issuance of common stock under Employee Stock Purchase Plan | 270,516 | - | 1,613 | - | - | 1,613 |
| Vesting of restricted stock units | 620,647 | 1 | (1) | - | - | - |
| Stock transaction associated with taxes withheld on restricted stock units | (53,567) | - | (463) | - | - | (463) |
| Stock-based compensation expense | - | - | 26,304 | - | - | 26,304 |
| Issuance of common stock in connection with At-The-Market sale, net of issuance costs of $2,026 | 10,285,160 | 11 | 56,259 | - | - | 56,270 |
| Net unrealized loss on available-for-sale securities | - | - | - | (304) | - | (304) |
| Net Loss | - | - | - | - | (119,204) | (119,204) |
| Balances at December 31, 2022 | 57,499,541 | $58 | $670,223 | $(618) | $(452,615) | $217,048 |
| Exercise of common stock options | 53,060 | - | 314 | - | - | 314 |
| Issuance of common stock under Employee Stock Purchase Plan | 526,079 | - | 2,051 | - | - | 2,051 |
| Vesting of restricted stock units | 1,155,644 | 1 | - | - | - | 1 |
| Stock transaction associated with taxes withheld on restricted stock units | (81,905) | - | (490) | - | - | (490) |
| Stock-based compensation expense | - | - | 24,908 | - | - | 24,908 |
| Issuance of common stock in connection with At-The-Market sale, net of issuance costs of $459 | 1,857,410 | 2 | 11,969 | - | - | 11,971 |
| Net unrealized income on available-for-sale securities | - | - | - | 639 | - | 639 |
| Net Loss | - | - | - | - | (106,793) | (106,793) |
| Balances at December 31, 2023 | 61,009,829 | $61 | $708,975 | $21 | $(559,408) | $149,649 |
| Exercise of common stock options | 63,748 | - | 271 | - | - | 271 |
| Issuance of common stock under Employee Stock Purchase Plan | 566,247 | - | 1,848 | - | - | 1,848 |
| Vesting of restricted stock units | 1,695,054 | 2 | (2) | - | - | - |
| Stock transaction associated with taxes withheld on restricted stock units | (114,585) | - | (509) | - | - | (509) |
| Stock-based compensation expense | - | - | 24,687 | - | - | 24,687 |
| Issuance of common stock in connection with the underwritten offering, net of issuance costs of $3,474 | 14,478,764 | 15 | 71,512 | - | - | 71,527 |
| Issuance of common stock to Ipsen Biopharmaceuticals, Inc. (USA) under the Ipsen Investment Agreement | 4,827,373 | 5 | 24,566 | - | - | 24,571 |
| Net unrealized income on available-for-sale securities | - | - | - | 18 | - | 18 |
| Net Loss | - | - | - | - | (227,461) | (227,461) |
| Balances at December 31, 2024 | 82,526,430 | $83 | $831,348 | $39 | $(786,869) | $44,601 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.